



Precision BioSciences to Report Fourth Quarter and Fiscal Year 2021 Results on March 15, 2022

March 8, 2022

DURHAM, N.C.--(BUSINESS WIRE)--Mar. 8, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS[®]-based *ex vivo* allogeneic CAR T and *in vivo* gene editing therapies, today announced that it will publish financial results for the fourth quarter and fiscal year 2021 and provide a business update on March 15, 2022.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS[®] genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple "off-the-shelf" CAR T immunotherapy clinical candidates and several *in vivo* gene editing therapy candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences please visit www.precisionbiosciences.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220308005213/en/): <https://www.businesswire.com/news/home/20220308005213/en/>

Investor Contact:

Alex Kelly
Chief Financial Officer
Alex.Kelly@precisionbiosciences.com

Media Contact:

Maurissa Messier
Senior Director, Corporate Communications
Maurissa.Messier@precisionbiosciences.com

Source: Precision BioSciences, Inc.